Complete regression of cardiac non-Hodgkin lymphoma.
Morillas
Pedro
P
Quiles
Juan
J
Nuñez
Daniel
D
Senent
Cristina
C
Martínez
Silvia
S
Fernández
Jose Antonio
JA
Bertomeu
Vicente
V
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004452:Echocardiography; D006338:Heart Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D000069283:Rituximab; D015899:Tomography, Emission-Computed, Single-Photon; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone